| Company/Division name | Novartis |
| Parent company | Novartis |
| Type of work | Manufacturing |
| Reshoring category: | Foreign Direct Investment |
| Total number of jobs (added or to be added): | 700 |
| Year reshoring announced: | 2025 |
| Year reshoring implemented or to be implemented: | 2030 |
| Capital investment ($): | 771 |
| Country(ies) from which reshored: | Switzerland |
| City reshored to: | Durham and Morrisville |
| State(s) reshored to: | NC |
| If relevant, work nearshored to: | - |
| Industry(ies): | Chemicals |
| Product(s) reshored | pharma |
| What non-domestic negative factors made offshoring less attractive? | Supply chain interruption |
| What domestic positive factors made reshoring more attractive? | Eco-system synergies, Proximity to customers/market |
